

Customer No. 28880

Confirmation No.

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/763,451	
	Filing Date	01/23/2004	
	First Named Inventor	Robert L. Dow	
	Art Unit	TBD	
	Examiner Name	TBD	
Total Number of Pages in This Submission	7	Attorney Docket Number	PC 10219B

RECEIVED
CENTRAL FAX CENTER
MAR 04 2004
OFFICIAL

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to a Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	IDS Statement
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks AUTHORIZATION TO CHARGE THE FEE AND ANY ADDITIONAL FEES AS NECESSARY OR CREDIT ANY OVERPAYMENT TO DEPOSIT ACCOUNT 23-0455 IS HEREBY GIVEN.		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual	J. Michael Dixon 32,410	
Signature		
Date	March 4, 2004	

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: March 4, 2004			
Typed or printed	Cicely M. Bohms	Date	March 4, 2004
Signature			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

USPTO Fax No. 703-872-9306

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/763,451
Applicant: ROBERT L. DOW
Filed: January 23, 2004
Title: 6-AZAUACIL DERIVATIVES AS THYROID RECEPTOR
LIGANDS

TC/A.U.: TBD
Examiner: TBD

Docket No.: PC10219B

RECEIVED
CENTRAL FAX CENTER

MAR 04 2004

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

OFFICIAL

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d); within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided except for issued United States patents or published patent applications.

In accordance with 37 C.F.R. §1.98(d), a copy of each document or other information listed is not provided because it was previously cited by or submitted to the U.S. Patent and Trademark Office in parent application, U.S. Serial No. filed on .

A concise explanation of the relevance of each non-English language document or other information is as follows (37 C.F.R. §1.98(a)(3)):


No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. §1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Dated: March 4, 2004



J. Michael Dixon, Reg. No. 32,410
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-1705
Fax (734) 622-1553
Customer No. 28880

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC10219B	SERIAL NO. 10/763,451
	APPLICANT Robert L. Dow, et al	
	FILING DATE 01/23/2004	GROUP To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	3	9	0	5	9	7	1	09/16/75	Miller	260	247.5 C	
	US	3	9	1	2	7	2	3	10/14/75	Miller	260	239.7	
	US	3	8	8	3	5	2	7	05/13/75	Brennan	260	248 AS	
	US	3	8	8	3	5	2	8	05/13/75	Mylari	260	248 AS	
	US	3	8	9	6	1	7	2	07/22/75	Mylari et al	260	578	
	US	3	8	5	2	2	8	9	12/03/74	Mylari et al	260	248 AS	
	US	3	8	8	2	1	1	5	05/06/75	Mylari	260	248 AS	
	US	3	8	8	3	5	2	5	05/13/75	Mylari	260	248 AS	
	US	5	2	5	6	6	3	1	10/26/93	Lindner et al	504	229	
	US	4	6	4	0	9	1	7	02/03/87	Rösner et al	514	222	
	US	4	1	9	8	4	0	7	04/15/80	Rösner et al	424	249	
	US	4	2	3	9	8	8	8	12/16/80	Miller	544	309	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	CA	9	7	9	4	5	7		09.12.75	Canada	260	248.6		
	CA	9	9	2	5	3	8		06.07.76	Canada	260	238.10		
	ZA	9	1	7	3	9	0		17.09.91	South Africa	C07D			
	DT*	2	5	3	2	3	6	3	03.02.77	Germany	C07D			
	DT*	2	3	5	8	8	5	1	12.08.74	Germany	C07D	55/06		
	EP	0	7	3	7	6	7	2	16.10.96	Europe (A2) & (A3)	C07C	281/14		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		A. H. Underwood, et al., Nature, Vol. 324: pp. 425-429 (1986).
		B. L. Mylari, et al., J. Med. Chem., 1977, Vol. 20, No. 4, 475-483, "Anticoccidial Derivatives of 6-Azauracil. 1. Enhancement of Activity by Benzoylation of Nitrogen-1. Observations on the Design of Nucleotide Analogues in Chemotherapy."
		M. W. Miller, et al., J. Med. Chem., 1979, Vol. 22, No. 12, 1483-1487, "Anticoccidial Derivatives of 6-Azauracil. 2. High Potency and

INFORMATION DISCLOSURE CITATION LIST.DOT, 3/93

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. <u>PC10219B</u>	SERIAL NO. <u>10/763,451</u>
		APPLICANT <u>Robert L. Dow, et al</u>	
		FILING DATE <u>01/23/2004</u>	GROUP <u>To be assigned</u>
		Long Plasma Life of N1-Phenyl Structures ^{1,2} .	
		M. W. Miller, et al., J. Med. Chem., 1980, Vol. 23, No. 10, 1083-1087, "Anticoccidial Derivatives of 6-Azauracil. 3. Synthesis, High Activity, and Short Plasma Half-Life of 1-Phenyl-6-azauracils Containing Sulfonamide Substituents ¹ ."	
		M. W. Miller, et al., J. Med. Chem., 1981, Vol. 24, No. 11, 1337-1342, "Anticoccidial Derivatives of 6-Azauracil. 4. A 1000-fold Enhancement of Potency by Phenyl Sulfide and Phenyl Sulfone Side Chains ¹ ."	
		R. D. Carroll, et al., J. Med. Chem., 1983, Vol. 26, No. 1, 96-100, "Anticoccidial Derivatives of 6-Azauracil. 5. Potentiation by Benzophenone Side Chains ¹ ."	
		K.-B. Rhyu, et al., J. Chem. Inf. Comput. Sci., 1996, Vol. 36, No. 3, "A 3D-QSAR Study of Anticoccidial Triazines Using Molecular Shape Analysis."	
		K.-B. Rhyu, et al., J. Chem. Inf. Comput. Sci., 1995, Vol. 35, No. 4, 771-778, "a 3D-QSAR Study of Anticoccidial Triazines Using Molecular Shape Analysis."	
		A. C. Good, et al., J. Med. Chem., 1993, Vol. 36, No. 20, 2929-2937, "QSAR's from Similarity Matrices. Technique Validation and Application in the Comparison of Different Similarity Evaluation Methods."	
		J. W. McFarland, J. Med. Chem., 1992, Vol. 35, No. 14, 2543-2550, "Comparative Molecular Field Analysis of Anticoccidial Triazines ¹ ."	
		J. W. McFarland, et al., J. Med. Chem., 1991, Vol. 34, No. 6, 1908-1911, "Linear Discriminant and Multiple Regression Analyses of Anticoccidial Triazines ¹ ."	
		• A. N. Chekhlov, et al., Dokl. Akad. Nauk (1993), 329 (5), 603-7.	
		• N. S. Zefirov, et al., Dokl. Akad. Nauk (1992), 327 (4-6), 504-8.	
		A. P. Ricketts, et al., Antimicrobial Agents and Chemotherapy, Oct. 1992, Vol. 36, pp. 2338-2341, "In Vivo Expression of In Vitro Anticoccidial Activity ¹ ."	
		M. J. Lynch, et al., J. Agric. Food Chem., Vol. 25, No. 6, pp. 1344-53, 1977, "Tissue Residue and Comparative Metabolism Studies on Tiazuril in the Chicken, Rat, Dog, and Monkey."	
		J. F. Ryley, et al., Parasitology (1974), 68, 69-79, "Anticoccidial activity of an azauracil derivative."	
		• English language translations will be provided as soon as available.	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

INFORMATION DISCLOSURE CITATION LIST.DOT, 9/99

INFORMATION DISCLOSURE

INFORMATION DISCLOSURE CITATION LIST.DOT. 9/99